Showing results (381-390 of 453) with videos related to
Sort By:
Pageof 46
Molecules (Basel, Switzerland)|December 23, 2020
PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor ResponseAladdin Riad, Sarah B Gitto, Hwan Lee, et al.Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Mu-opioid receptor availability in patients with opioid use disorder treated with either methadone or buprenorphineJacob G Dubroff, Chia-Ju Hsieh, Hsiaoju Lee, et al.Journal of Medicinal Chemistry|March 11, 2025
Structure-Activity Relationships and Evaluation of 2-(Heteroaryl-cycloalkyl)-1H-indoles as Tauopathy Positron Emission Tomography RadiotracersJeffrey S Stehouwer, Guofeng Huang, Dinahlee Saturnino Guarino, et al.Synapse (New York, N.Y.)|April 1, 1997
Imaging of cholinergic terminals using the radiotracer [18F](+)-4-fluorobenzyltrozamicol: in vitro binding studies and positron emission tomography studies in nonhuman primatesR H Mach, M L Voytko, R L Ehrenkaufer, et al.Bioorganic & Medicinal Chemistry Letters|August 8, 2019
Design, synthesis, and evaluation of N-(4-(4-phenyl piperazin-1-yl)butyl)-4-(thiophen-3-yl)benzamides as selective dopamine D3 receptor ligandsPeng-Jen Chen, Michelle Taylor, Suzy A Griffin, et al.Journal of Medicinal Chemistry|November 12, 1993
18F-labeled benzamides for studying the dopamine D2 receptor with positron emission tomographyR H Mach, R R Luedtke, C D Unsworth, et al.Molecular Cancer|July 17, 2007
Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapyHiroyuki Kashiwagi, Jonathan E McDunn, Peter O Simon, et al.Nuclear Medicine and Biology|October 28, 2017
Consensus nomenclature rules for radiopharmaceutical chemistry - Setting the record straightHeinz H Coenen, Antony D Gee, Michael Adam, et al.Neurology|August 9, 2006
[11C]PIB in a nondemented population: potential antecedent marker of Alzheimer diseaseM A Mintun, G N Larossa, Y I Sheline, et al.Cancer Research|June 5, 2016
A Radiotracer Strategy to Quantify PARP-1 Expression In Vivo Provides a Biomarker That Can Enable Patient Selection for PARP Inhibitor TherapyMehran Makvandi, Kuiying Xu, Brian P Lieberman, et al.Pageof 46